Skip to content
AwardedSpainGoods€141,023,870

Suministro, respetuoso con el medio ambiente, de medicamentos de uso humano cuyos principios activos son mavacamten, fedratinib, abatacept, ipilimumb, nivolumab, luspatercept, cobicistat/atazanavir, deucravanacitinib y ozanimod, con destino a los centros del ámbito de la sanidad pública valenciana

Published
Published 19 February 2025

Overview

Suministro, respetuoso con el medio ambiente, de medicamentos de uso humano cuyos principios activos son mavacamten, fedratinib, abatacept, ipilimumb, nivolumab, luspatercept, cobicistat/atazanavir, deucravanacitinib y ozanimod, con destino a los centros del ámbito de la sanidad pública valenciana

Key details

Country
Spain
Status
Awarded
Category
Goods
Estimated value
€141,023,870
Procedure
Direct
Published
19 February 2025
Classification (CPV)
Antianaemic preparationsCardiac therapy medicinal productsAntivirals for systemic useAntineoplastic agentsImmunosuppressive agents

Award outcome

Awarded value
€0
Award date
25 November 2025
Winner
  • BRISTOL-MYERS SQUIBB, S.A.U.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    31 December 2025

  2. Contract Notice

    19 February 2025

Contracting authority

  • Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad

    Procuring entity

    Valencia, Spain

    ID_PLATAFORMA: 20897030133463

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Suministro, respetuoso con el medio ambiente, de medicamentos de uso humano cuyos principios activos son mavacamten, fedratinib, abatacept, ipilimumb, nivolumab, luspatercept, cobicistat/atazanavir, deucravanacitinib y ozanimod, con destino a los centros del ámbito de la sanidad pública valenciana — won by BRISTOL-MYERS SQUIBB, S.A.U. — Skim